A new series of DPPYs were synthesized and biologically evaluated as potent BTK inhibitors. DPPYs could inhibit BTK activity at nanomolar concentrations. Inhibitor 7j displayed higher inhibitory capacity to interfere with B leukemia cell lines than ibrutinib. Inhibitor 7j has low cell cytotoxicity against normal PBMC cells.